Biogen and Eisai, two American pharmaceutical companies, have created a monochlorinated drug, which is laboratory-produced proteins that simulate the functioning of the immune system, called “Leconemab.” This drug, Leconemab, reduces the accumulation of the amyloid protein, limiting the progression of Alzheimer’s neurodegenerative disease, leading to more effective results if the patient takes it when the...Read More